Food, drug, insect sting allergy, and anaphylaxisAnaphylaxis in children and adolescents: The European Anaphylaxis Registry
Section snippets
Setting and design
The European Anaphylaxis Registry collected information on anaphylactic reactions through a Web-based data entry system. Data for the current analysis were provided by tertiary referral centers specialized in pediatric allergology, dermatology, or both in Germany, France, Switzerland, Ireland, Greece, Austria, Spain, Bulgaria, Italy, and Poland. The study was approved by the Ethics Committee at Charité - Universitätsmedizin Berlin (the coordinating center) and by the local ethics committees in
Study centers and participants
The European Anaphylaxis Registry collected data on 1970 children from 90 study centers in 10 countries: Germany (n = 1040), France (n = 321), Switzerland (n = 297), Ireland (n = 95), Greece (n = 86), Austria (n = 59), Spain (n = 36), Bulgaria (n = 25), Italy (n = 6), and Poland (n = 5). Six hundred ninety-two (35%) were female, with a higher female proportion in adolescents (43%). All ages (in 1-year intervals) were represented similarly, except for infants (<1 year, n = 18) and 1-year-old
Key results
With 1970 patients, this is the first large-scale description of pediatric anaphylaxis. More data were collected on boys (about two thirds) than on girls, but the European Anaphylaxis Registry covered all age groups, including a sparsely populated first year of life. Although sex differences have been described for several allergic diseases,24 the sampling scheme used here does not support the interpretation of skewed distributions of age, sex, or other baseline information. One in 3 children
References (27)
- et al.
International consensus on (ICON) anaphylaxis
World Allergy Organ J
(2014) - et al.
Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
J Allergy Clin Immunol
(2006) - et al.
Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years)
J Allergy Clin Immunol
(2015) Anaphylaxis in infants: can recognition and management be improved?
J Allergy Clin Immunol
(2007)- et al.
Anaphylaxis epidemic: fact or fiction?
J Allergy Clin Immunol
(2008) - et al.
Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States
J Allergy Clin Immunol
(2014) - et al.
Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990-2006
Ann Allergy Asthma Immunol
(2008) - et al.
Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an analysis of the Italian Ministry of Health database
J Allergy Clin Immunol
(2015) - et al.
Incidence and severity of anaphylactoid reactions to colloid volume substitutes
Lancet
(1977) - et al.
Age-related differences in the clinical presentation of food-induced anaphylaxis
J Pediatr
(2011)
Anaphylaxis in the community: learning from the survivors
J Allergy Clin Immunol
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology
Allergy
The management of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology
Allergy
Cited by (404)
Implementation of a stock of epinephrine: Is it necessary for all schools?
2024, Revue Francaise d'AllergologieAnaphylaxis: A 2023 practice parameter update
2024, Annals of Allergy, Asthma and ImmunologyPhysician adherence to anaphylaxis guidelines among different age groups in emergency departments: 20-Year observational study
2024, Annals of Allergy, Asthma and ImmunologyAnaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets
2024, Journal of Allergy and Clinical Immunology: In PracticeApproach to Idiopathic Anaphylaxis in Adolescents
2024, Medical Clinics of North America
The European Anaphylaxis Registry was supported by the Network for Online Registration of Anaphylaxis NORA e. V. The Polish study center received support from the Medical University of Lodz Research Fund (503/1-137-01/503-11-001). The Irish study center received a funding grant from the National Children's Research Centre, Dublin, Ireland.
Disclosure of potential conflict of interest: L. Lange receives payments from Thermo Fisher Scientific, ALK-Abelló, and Novartis. T, Spindler is a member of the Fultiform Advisory Board. F. Ruëff is board member for ALK-Abelló and Firma Bencard; serves as a consultant for DST; serves as an expert on the Advisory Board for ALK-Abelló and Bencard; and has received payments for lectures from Semperit Technische Produkte Gesellschaft, Novartis, Stallergenes, and MEDA Pharma GmbH & Co. E. Roumpedaki receives travel support from Allergie Centrum Charité. M. Fernandez-Rivas serves as a consultant for DBV and Reacta Biotech; has grants pending from the European Union and Spanish Ministry of Science; receives payments for lectures for ALK-Abelló, Merck, and GlaxoSmithKline; and receives travel support from the European Academy of Allergy and Clinical Immunology and Fundacion SEAIC. J. O'B. Hourihane receives research funding from the National Childrens Research Centre, Ireland; serves as a consultant from Aimmune Corporation; receives speaker fees from Thermo Fisher Scientific; and is the Chairman of Irish Food Allergy Network, which receives unrestricted funding for educational purposes from infant formula and adrenaline injector manufacturers. N. G. Papadopoulos receives research funding from GlaxoSmithKline, Nestlè, and Merck; receives payment for development of educational presentations from Abbvie, Sanofi, Menarini, and Meda; serves as a consultant for GlaxoSmithKline, Abbvie, Novartis, Menarini, Meda and ALK-Abelló; and receives payment for lectures from Novartis, AllergoPharma, Uriach, GlaxoSmithKline, Stallergens, and MSD. K. Beyer serves as a consultant for Meda Pharma, Bausch & Lomb, and ALK-Abelló and receives speaker fees from ALK-Abelló and Meda Pharma. M. Worm serves as a consultant and receives speaker fees for ALK-Abelló and receives travel support form Meda Pharma. The rest of the authors declare that they have no relevant conflicts of interest.